Navigation Links
Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
Date:11/8/2012

CRANBURY, N.J., Nov. 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).

The data demonstrate that women taking bremelanotide showed statistically significant increases in the number of Satisfying Sexual Events (SSEs) and also showed statistically significant improved measures of overall sexual functioning and distress related to sexual dysfunction, compared with placebo.

The primary endpoint data analysis of 327 pre-menopausal women with female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or a combination of both disorders, the most common types of FSD, shows a clinically meaningful and statistically significant improvement (p=0.018) in the number of SSEs in women taking bremelanotide doses (mean change from 1.6 at baseline increasing to 2.4; pooled 1.25 mg and 1.75 mg doses) versus placebo (mean change from 1.7 at baseline increasing to 1.9) over the study period, resulting in a 50% increase in SSEs with bremelanotide versus 12% with placebo.

"We are extremely pleased to report the successful completion of this trial, which achieved statistical significance in our primary endpoint and key secondary endpoints using independently developed and validated measurement tools. Importantly, we met the objectives of the trial which demonstrated excellent safety and efficacy of the drug and identified doses for advancement into Phase 3 trials and activities" stated Carl Spana, Ph.D., President and CEO of Palatin. "Our next steps are to continue to compile and analyze additional data, to start the preparation process for an end-of-Phase 2 meeting with the FDA, and to further our discussions with potential colla
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi ... patient recruitment services. The core expertise of PRC Clinical is focused on Clinical ...
(Date:7/29/2015)... ... July 29, 2015 , ... Costello served as Lead ... to protect the Orange County, Texas area from future storm surge flooding, such ... in determining several potential levee alignment alternatives for providing protection, Costello also balanced socio-economic ...
(Date:7/29/2015)... ... July 29, 2015 , ... Asymmetrex, ... good progress in evaluating the full range of capabilities of its unique cache ... stem cells perform the day-to-day renewal and repair of normal tissues and organs. ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Preventing Storm Surge Flooding in Houston 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4
... CARLSBAD, Calif., May 4 GenVault Corporation is delighted ... Sales and Marketing. With over 25 years of ... of driving sales growth in both the domestic and ... held the position of Vice President of Sales, Americas, ...
... Laboratories, Inc. announced today the launch of its ... Tablets by the U.S. Food and Drug Administration. ... Bottles of 100 and 500, 500mg Tablets Bottles ... for immediate shipment to wholesalers and pharmacies nationwide.(Photo: ...
... May 4 Circ Pharma Limited ("Circ Pharma") ... have entered into a,Development Agreement to develop a ... to moderately severe pain. , ... delivery,technology enabling once daily dosing. Circ,s technology provides ...
Cached Biology Technology:Shane Lyons Joins GenVault Corporation as Vice President of Sales and Marketing 2Shane Lyons Joins GenVault Corporation as Vice President of Sales and Marketing 3Roxane Laboratories, Inc. Announces the Launch of Mycophenolate Mofetil 250mg Capsules and 500mg Tablets 2Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc 2
(Date:7/21/2015)... -- Today, ZTE announced its Android smartphone Axon, featuring ... revenues in 2015 that relate to sales of FPC1025 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... China and we are proud that ... Axon , its first ...
(Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
(Date:7/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the fourth quarter and ... the close of market. The company will host a ... p.m. PT (5:00 p.m. ET), during which management may ... the live call, analysts and investors should dial 888-455-2260 ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... in BioMed Central,s open access journal BMC Genomics ... with its 50cm diameter flowers, has ,stolen, genes from its ... that their functions range from respiration to metabolism, and that ... activity. Vertical gene transfer is that between parents and ...
... toy ecosystem modeling and paleontological evidence as a crystal ... predict we,re on a much worse collision course with ... Approaching a state-shift in Earth,s biosphere, a paper just ... span a multitude of disciplines, suggest our planet,s ecosystems ...
... Working with researchers at the University of Pittsburgh ... Barbara have found high levels of beneficial omega-3 fatty ... woman as compared to women in the United States. ... journal Maternal and Child Nutrition . The ...
Cached Biology News:Parasitic plants 'steal' genes from their hosts 2Study predicts imminent irreversible planetary collapse 2UCSB anthropologists finds high levels of omega-3 fatty acids in breast milk of Amerindian women 2
8.1.1...
Human SCP3 Affinity Purified Polyclonal Ab Keywords: Spermatogenesis, meiosis Protein Family: Cell Cycle...
... and efficient purification of DNA and oligonucleotides ... by gravity flow.Prepacked with Sephadex G-25 DNA ... CG/ICP Biocide.Available in three sizes depending on ... ml (NAP-10) or 2.5 ml (NAP-25).Useful for ...
Homo sapiens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA....
Biology Products: